In:
Drug Metabolism and Personalized Therapy, Walter de Gruyter GmbH, Vol. 38, No. 1 ( 2023-03-14), p. 45-56
Kurzfassung:
Symptomatic remediation from attention deficit hyperactivity disorder (ADHD)-associated traits is achieved by treatment with methylphenidate (MPH)/atomoxetine (ATX). We have analyzed the association of functional CYP2D6 variations, rs1065852, rs3892097, rs1135840, and rs1058164, with ADHD in the Indian subjects. Methods Subjects were recruited following the Diagnostic and Statistical Manual for Mental Disorders. Trait scores were obtained from the Conner’s Parents Rating Scale-Revised. After obtaining informed consent, blood was collected for DNA isolation, and genotyping was performed by PCR or TaqMan-based methods. Probands were treated with MPH or ATX based on age, symptoms, and drug availability. Treatment outcome was assessed using a structured questionnaire. Data obtained was analyzed to identify the association of CYP2D6 variations and the SLC6A3 rs28363170 with the treatment outcome. Results The frequency of rs1135840 “G” and rs1065852 “G” was higher in the male ADHD probands. Bias in parental transmission (p=0.007) and association with higher trait scores were observed for rs1065852 “A”. Independent influence of rs1065852 on ADHD was also observed. Probands carrying rs1065852 ‘GG’, rs1135840 ‘CG’, and rs28363170 10R exhibited significant symptomatic improvement with MPH, while probands with rs1135840 ‘CC’ and rs28363170 9R showed improvement after ATX treatment. Conclusions ADHD probands having specific CYP2D6 genetic variations respond differentially to pharmaceutical intervention.
Materialart:
Online-Ressource
ISSN:
2363-8915
DOI:
10.1515/dmpt-2022-0120
Sprache:
Englisch
Verlag:
Walter de Gruyter GmbH
Publikationsdatum:
2023
ZDB Id:
2822040-7
